Boris Bikbov1,2, Brian Bieber3, Anton Andrusev1,4, Natalia Tomilina1,2,4, Alexander Zemchenkov5, Junhui Zhao3, Friedrich Port3, Bruce Robinson3, Ronald Pisoni3. 1. Department of Nephrology, A.I.Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation. 2. Department of Nephrology Issues of Transplanted Kidney, Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation. 3. Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA. 4. Moscow City Nephrology Center, City Clinical Hospital #52 of Moscow City Health Department, Moscow, Russian Federation. 5. Department of Nephrology and Dialysis, I.P.Pavlov First St-Petersburg State Medical University, St. Petersburg, Russia.
Abstract
INTRODUCTION: There is little comparable information about hemodialysis (HD) practices in low- and middle income countries, including Russia. Evaluation of HD in Russia and its international comparisons could highlight factors providing opportunities for improvement. METHODS: We examined treatment patterns for 481 prevalent HD patients in 20 Russian facilities, and compared them to contemporary data for 8512 patients from 311 facilities in seven European countries, Japan, and North America. Data were collected according to the uniform methodology of the Dialysis Outcomes and Practice Patterns Study, phase 5. FINDINGS: Compared to other regions, Russian patients were younger (mean age 53.4 years), had a lower percent of males (52.5%), higher arteriovenous fistula use (89.7%), and longer treatment time (mean: 252 minutes, SD: 37 minutes). Mean single pool Kt/V was 1.49 (SD 0.58). Prescription of dialysate calcium 3.5 mEq/L and aluminum-based phosphate binders were high (15.2% and 17.6% of patients, respectively), while intravenous vitamin D and cinacalcet were low (3.3% and 2.2%, respectively). The percents with parathyroid hormone >600 pg/mL (30.9%) and serum phosphate >1.78 mmol/L (37.7%) were high. Use of erythropoetin stimulating agents (78%) was lower, but hemoglobin, ferritin, and transferrin saturation were generally comparable to North America and Europe. DISCUSSION: These detailed data for hemodialysis in Russia demonstrate that many practice patterns contrasted sharply to those in Europe, Japan, and North America, while other features were similar. Our analysis revealed several positive and some less favorable treatment patterns in Russia that represent opportunities for improving patient care and outcomes.
INTRODUCTION: There is little comparable information about hemodialysis (HD) practices in low- and middle income countries, including Russia. Evaluation of HD in Russia and its international comparisons could highlight factors providing opportunities for improvement. METHODS: We examined treatment patterns for 481 prevalent HDpatients in 20 Russian facilities, and compared them to contemporary data for 8512 patients from 311 facilities in seven European countries, Japan, and North America. Data were collected according to the uniform methodology of the Dialysis Outcomes and Practice Patterns Study, phase 5. FINDINGS: Compared to other regions, Russian patients were younger (mean age 53.4 years), had a lower percent of males (52.5%), higher arteriovenous fistula use (89.7%), and longer treatment time (mean: 252 minutes, SD: 37 minutes). Mean single pool Kt/V was 1.49 (SD 0.58). Prescription of dialysate calcium 3.5 mEq/L and aluminum-based phosphate binders were high (15.2% and 17.6% of patients, respectively), while intravenous vitamin D and cinacalcet were low (3.3% and 2.2%, respectively). The percents with parathyroid hormone >600 pg/mL (30.9%) and serum phosphate >1.78 mmol/L (37.7%) were high. Use of erythropoetin stimulating agents (78%) was lower, but hemoglobin, ferritin, and transferrin saturation were generally comparable to North America and Europe. DISCUSSION: These detailed data for hemodialysis in Russia demonstrate that many practice patterns contrasted sharply to those in Europe, Japan, and North America, while other features were similar. Our analysis revealed several positive and some less favorable treatment patterns in Russia that represent opportunities for improving patient care and outcomes.
Authors: Issa Al Salmi; Brian Bieber; Mona Al Rukhaimi; Ali AlSahow; Faissal Shaheen; Saeed M G Al-Ghamdi; Jamal Al Wakeel; Fadwa Al Ali; Ali Al-Aradi; Fayez Al Hejaili; Yacoub Al Maimani; Essam Fouly; Bruce M Robinson; Ronald L Pisoni Journal: Kidney360 Date: 2020-08-26
Authors: Ladan Golestaneh; Kerri L Cavanaugh; Yungtai Lo; Angelo Karaboyas; Michal L Melamed; Tanya S Johns; Keith C Norris Journal: Am J Kidney Dis Date: 2020-07-13 Impact factor: 8.860
Authors: Douglas S Fuller; David Hallett; Paul J Dluzniewski; Bruno Fouqueray; Michel Jadoul; Hal Morgenstern; Friedrich K Port; Francesca Tentori; Ronald L Pisoni Journal: BMC Nephrol Date: 2019-05-14 Impact factor: 2.388
Authors: Mario Cozzolino; Eugeniy Shilov; Zuo Li; Masafumi Fukagawa; Saeed M G Al-Ghamdi; Ronald Pisoni; Brian Bieber; Bhadrish Vallabh; Deepa H Chand Journal: Adv Ther Date: 2020-05-14 Impact factor: 3.845
Authors: Ladan Golestaneh; Angelo Karaboyas; Kerri Cavanaugh; Ebele M Umeukeje; Tanya S Johns; Roland J Thorpe; Marino A Bruce; Derek M Griffith; Michal L Melamed; Keith C Norris Journal: Kidney Int Rep Date: 2020-10-20